|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 274.44 USD | -0.47% |
|
-1.27% | -4.61% |
| Capitalization | 15TCr 14TCr 13TCr 12TCr 21TCr 12,57900Cr 23TCr 1,62800Cr 60TCr 5,16500Cr 56TCr 54TCr 22,54000Cr | P/E ratio 2024 * |
29.3x | P/E ratio 2025 * | 23.4x |
|---|---|---|---|---|---|
| Enterprise value | 20TCr 19TCr 17TCr 15TCr 28TCr 16,68800Cr 31TCr 2,16000Cr 80TCr 6,85200Cr 74TCr 72TCr 29,90400Cr | EV / Sales 2024 * |
5.98x | EV / Sales 2025 * | 5.59x |
| Free-Float |
99.75% | Yield 2024 * |
3.28% | Yield 2025 * | 3.51% |
More valuation ratios
* Estimated data
More news
Last Transcript: Amgen Inc.
More recommendations
More press releases
More news
| 1 day | -0.68% | ||
| 1 week | -0.92% | ||
| Current month | -2.52% | ||
| 1 month | -15.23% | ||
| 3 months | -16.17% | ||
| 6 months | -9.51% | ||
| Current year | -4.26% |
1 week
271.48
280.00
1 month
257.80321.22
Current year
257.80346.85
1 year
257.80346.85
3 years
209.00346.85
5 years
177.05346.85
10 years
130.09346.85
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/05/2012 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 01/01/2020 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 26/07/2018 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 61 | 01/01/2013 |
Tyler Jacks
BRD | Director/Board Member | 63 | 01/01/2012 |
Robert Eckert
BRD | Director/Board Member | 69 | 01/01/2003 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 139 M€ | +25.85% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.68% | -0.92% | +2.46% | +30.76% | 15TCr | ||
| -0.50% | -1.69% | +33.70% | +227.51% | 72TCr | ||
| +0.28% | +0.73% | +17.41% | +106.19% | 49TCr | ||
| -0.25% | -2.05% | -3.36% | -9.83% | 36TCr | ||
| -0.51% | -3.21% | +17.68% | +40.01% | 31TCr | ||
| -2.69% | -0.83% | -2.65% | +39.08% | 26TCr | ||
| +0.45% | +0.55% | +0.31% | -32.03% | 23TCr | ||
| -0.18% | +0.13% | +3.94% | +27.23% | 21TCr | ||
| -0.58% | -2.03% | +3.14% | +18.42% | 20TCr | ||
| -2.03% | +0.04% | -11.15% | -51.55% | 14TCr | ||
| Average | -0.17% | -1.53% | +6.15% | +39.58% | 30.66TCr | |
| Weighted average by Cap. | -0.14% | -1.53% | +11.95% | +76.16% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 3.29TCr 3.13TCr 2.9TCr 2.58TCr 4.66TCr 2,79200Cr 5.16TCr 36TCr 13TCr 1,14600Cr 12TCr 12TCr 5,00300Cr | 3.43TCr 3.26TCr 3.02TCr 2.69TCr 4.85TCr 2,90900Cr 5.38TCr 38TCr 14TCr 1,19400Cr 13TCr 13TCr 5,21200Cr |
| Net income | 515.52Cr 490.67Cr 454.71Cr 404.44Cr 730.09Cr 44TCr 809.11Cr 5.66TCr 2.09TCr 18TCr 1.94TCr 1.89TCr 78TCr | 646.98Cr 615.8Cr 570.67Cr 507.58Cr 916.27Cr 55TCr 1.02TCr 7.11TCr 2.62TCr 23TCr 2.43TCr 2.38TCr 98TCr |
| Net Debt | 4.84TCr 4.61TCr 4.27TCr 3.8TCr 6.86TCr 4,11000Cr 7.6TCr 53TCr 20TCr 1,68700Cr 18TCr 18TCr 7,36400Cr | 4.34TCr 4.13TCr 3.83TCr 3.4TCr 6.14TCr 3,68100Cr 6.81TCr 48TCr 18TCr 1,51100Cr 16TCr 16TCr 6,59600Cr |
More financial data
* Estimated data
Employees
26,700
Sector
Pharmaceuticals
Calendar
04/02/2025
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/24/12 | 274.83 $ | -0.33% | 1,533,718 |
| 10/24/10 | 275.75 $ | -0.68% | 2,791,398 |
| 09/24/09 | 277.63 $ | +1.85% | 3,222,458 |
| 06/24/06 | 272.58 $ | -0.64% | 3,970,337 |
| 05/24/05 | 274.33 $ | -1.41% | 3,186,985 |
Delayed Quote Nasdaq, December 11, 2024 at 02:30 am IST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
275.75USD
Average target price
328.13USD
Spread / Average Target
+18.99%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition